Immunometabolic control of trained immunity by Riksen, N.P. & Netea, M.G.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-02 and may be subject to
change.
Molecular Aspects of Medicine 77 (2021) 100897
Available online 2 September 2020
0098-2997/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Review 
Immunometabolic control of trained immunity 
Niels P. Riksen *, Mihai G. Netea 
Dept. of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, the 
Netherlands   
A R T I C L E  I N F O   
Keywords: 
Trained immunity 





A B S T R A C T   
Innate immune cells can adopt long-term inflammatory phenotypes following brief encounters with exogenous 
(microbial) or endogenous stimuli. This phenomenon is named trained immunity and can improve host defense 
against (recurrent) infections. In contrast, trained immunity can also be maladaptive in the context of chronic 
inflammatory disorders, such as atherosclerosis. Key to future therapeutic exploitation of this mechanism is 
thorough knowledge of the mechanisms driving trained immunity, which can be used as pharmacological targets. 
These mechanisms include profound changes in intracellular metabolism, which are closely intertwined with 
epigenetic reprogramming at the level of histone modifications. Glycolysis, glutamine replenishment of the 
tricarboxylic acid cycle with accumulation of fumarate, and the mevalonate pathway have all been identified as 
critical pathways for trained immunity in monocytes and macrophages. In this review, we provide a state-of-the- 
art overview of how these metabolic pathways interact with epigenetic programs to develop trained immunity.   
1. Introduction 
Pharmacological modulation of the immune system has taken central 
stage in the prevention and treatment of a wide variety of diseases. 
Vaccination strategies exploit the immunological memory of the adap-
tive immune system to prevent infectious diseases. In patients with se-
vere infections, host directed therapy aimed at modulating the immune 
system is a promising emerging approach (Kaufmann et al., 2018). 
Immunosuppressive drugs are the cornerstone of the treatment of pa-
tients with auto-immune or auto-inflammatory diseases, such as rheu-
matoid arthritis, psoriasis, and inflammatory bowel disease. Also in 
patients with atherosclerotic cardiovascular diseases, which are char-
acterized by a chronic low-grade inflammation of the arterial wall, 
immunomodulating drugs such as canakinumab and colchicine are 
effective in reducing future cardiovascular events (Ridker et al., 2017; 
Tardif et al., 2019). 
Modulating immune system function is not trivial and is often 
associated with unwanted side effects, such as an increased risk of in-
fections in the case of immunosuppressive drugs. To allow the devel-
opment of more specific immunomodulatory drugs with less side effects, 
a deeper understanding of immune cell function in physiological and 
pathophysiological conditions is warranted. In the past ten years, it has 
been discovered that innate immune cells, such as monocytes, macro-
phages, and natural killer cells, can also build an immunological 
memory, in a process which has been termed trained immunity (Netea 
et al., 2020). Key intracellular processes that regulate trained immunity 
include remodeling of intracellular metabolic pathways as well as 
epigenetic reprogramming. Accumulating evidence points to an impor-
tant role for trained immunity in a broad spectrum of (patho)physio-
logical conditions (Netea et al., 2020). Therefore, it has recently been 
proposed that specific pathways that drive trained immunity offer 
exciting novel pharmacological targets to modulate immune cell func-
tion (Mulder et al., 2019). 
The aim of the present review is to provide a state-of-the-art over-
view of the role of immunometabolism in trained immunity. We will first 
describe the triggers and functional effects of trained immunity in the 
context of various clinical situations. Subsequently, we will describe in 
detail how changes in glycolysis, the tricarboxylic acid cycle (TCA cycle) 
and glutaminolysis, oxidative phosphorylation, fatty acid synthesis, and 
cholesterol biosynthesis contribute to innate immune memory and how 
these pathways interact with epigenetic programs. Finally, we will 
describe how we can use the knowledge of these mechanisms to ulti-
mately exploit trained immunity to improve patient care. 
2. Trained immunity 
In the traditional immunological dogma, immune memory is 
restricted to the adaptive immune system in which T-lymphocytes can 
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develop a life-long specific immunological memory by somatic rear-
rangement of gene elements. This is challenged however by the obser-
vations that also plants and non-vertebrate species, which lack adaptive 
immunity, are able to mount resistance to recurrent infections (Netea, 
Quintin, and van der Meer, 2011). Only in the last decade, our lab and 
others have shown that indeed monocytes are also able to build a 
long-term pro-inflammatory phenotype after primary stimulation, i.e. a 
de facto immune memory (Kleinnijenhuis et al., 2012; Quintin et al., 
2012). 
In the classical experimental design to investigate trained immunity 
in vitro, isolated human primary monocytes are exposed for 24 h to a 
microorganism or a microbial ligand; subsequently the cells are washed 
and rested in culture medium for 6 days, after which they are restimu-
lated for 24 h with unrelated stimuli, such as Toll-like receptor agonists: 
the boosting of cytokine production compared to cells not exposed to the 
training agent is calculated as a marker of trained immunity (Bekkering 
et al., 2016). It appeared that cytokine production capacity is pro-
foundly augmented after 24 h exposure to various micro-organisms or 
microbial products, including Bacille Calmette-Guérin (BCG), Candida 
albicans, and its cell wall component β-glucan. This observation could be 
corroborated in humans in vivo by showing enhanced cytokine pro-
duction capacity of isolated monocytes up to one year after 
BCG-vaccination of healthy individuals (Kleinnijenhuis et al., 2014). 
The remarkable evolutionary conservation of trained immunity is 
probably related to its strong protective effect in the setting of recurrent 
infections, which has been demonstrated in multiple animal models. In 
T/B cell-defective Rag1-deficient mice, a nonlethal dose of live 
C. albicans improves survival rate following subsequent exposure to 
systemic candidiasis (Quintin et al., 2012). Also, in severe combined 
immunodeficiency mice that lack T and B cells, BCG vaccination 
completely prevents mortality by an otherwise lethal C. albicans infec-
tion (Kleinnijenhuis et al., 2012). That trained immunity is able to 
protect the host against future infections is also suggested in human in 
vivo infection models: first, viremic load following yellow fever vacci-
nation (which is a live attenuated virus) was significantly reduced by 
BCG vaccination 28 days earlier in healthy subjects (Arts et al., 2018); 
secondly, BCG vaccination alters the clinical and immunological 
response to experimental malaria infection in healthy subjects (Walk 
et al., 2019). Given these experimental findings, trained immunity is a 
plausible explanation for the clinical observation that in newborns, BCG 
vaccination potently protects against a wide range of severe infections, 
not only against tuberculosis (Benn et al., 2013). Studies on the use of 
the BCG vaccine with the sole aim to exploit these beneficial heterolo-
gous effects of trained immunity in the clinical setting have been greatly 
accelerated by the recent pandemic caused by the severe acute respi-
ratory syndrome coronavirus-2 (SARS-CoV-2): several randomized 
clinical trials are currently being performed aiming to prevent corona-
virus disease 2019 (COVID-19) in subjects with increased risk, such as 
healthcare workers or elderly (Netea et al., 2020; Curtis et al., 2020). 
Contrasting the benefits of trained immunity in the setting of infec-
tious threats, it might actually be detrimental in non-infectious chronic 
inflammatory diseases in which innate immune cells themselves 
contribute to tissue injury, e.g. rheumatoid arthritis or atherosclerosis 
(Bekkering et al., 2013). Also, trained immunity might be one of the 
mechanisms to explain the well-known association between infectious 
diseases and cardiovascular disease (Leentjens et al., 2018). In vitro, 
various endogenous compounds that are known to accelerate the process 
of atherosclerosis, induce trained immunity in isolated human mono-
cytes. These factors include oxidized low-density lipoprotein (oxLDL) 
(Bekkering et al., 2014), lipoprotein (a) (van der Valk et al., 2016), and 
the adrenal hormones aldosterone (van der Heijden et al., 2020) and 
adrenaline and noradrenaline (van der Heijden et al., 2020). Feeding 
atherosclerosis prone LDL-receptor deficient mice a Western type diet for 
a period of four weeks induces profound inflammatory reprogramming 
of circulating innate immune cells, which persists despite switching diet 
back to chow diet (Christ et al., 2018). The relevance of these 
experimental findings is highlighted by the observation that isolated 
monocytes from patients with established severe coronary atheroscle-
rosis have a trained immune phenotype, in terms of an augmented 
cytokine production capacity ex vivo (Bekkering, van den Munckhof 
et al., 2016). This also holds true for patients with an increased risk for 
atherosclerotic cardiovascular disease due to elevated LDL-cholesterol 
levels (patients with familial hypercholesterolemia), in whom the 
augmented cytokine production capacity could not be restored by three 
months of LDL-cholesterol lowering with statin treatment (Bekkering 
et al., 2019). Similar findings have been obtained in patients with 
elevated lipoprotein (a) levels, and patients with pheochromocytoma, 
who are exposed to repetitive bouts of adrenal catecholamine release 
(van der Valk et al., 2016; van der Heijden et al., 2020). In these latter 
patients, the increased cytokine production capacity persisted for one 
month following surgical removal of the catecholamine-producing 
tumor, emphasizing the memory aspect of this phenotype. 
The observation that the enhanced cytokine production capacity that 
defines trained immunity persists for at least several months in humans 
in vivo – i.e. much longer than the half-life of circulating monocytes – 
prompted researchers to focus on the myeloid progenitor cells in the 
bone marrow niche. Indeed, in murine models, stimuli that induce 
trained immunity in circulating monocytes, including Western type diet 
feeding, BCG vaccination, or administration of β-glucan, were found to 
trigger a persistent inflammatory reprogramming of myeloid progenitor 
cells in the bone marrow (Christ et al., 2018; Kaufmann et al., 2018; 
Mitroulis et al., 2018). In healthy subjects, BCG vaccination also induced 
an inflammatory functional and transcriptional reprogramming of he-
matopoietic stem and progenitor cells, measured 90 days after vacci-
nation (Cirovic et al., 2020). 
To allow optimal future exploitation of the mechanism of trained 
immunity as pharmacological target, it is critical to be fully informed 
about the pathways that drive, maintain, and modulate innate immune 
memory. The two major processes that regulate this memory are 
epigenetic and metabolic reprogramming. Although these processes are 
regulated by separate sets of epigenetic and metabolic enzymes, there 
are close bilateral interactions connecting changes in metabolic path-
ways to epigenetic alterations and vice versa (Fig. 1). We will first briefly 
touch upon the essential epigenetic alterations in trained cells, followed 
by an extensive overview of the various metabolic changes and how 
these two processes interact. 
3. Epigenetic reprogramming in trained immunity 
Gene transcription is regulated by the binding of transcription factors 
and RNA polymerase at gene promoters that are proximal to the tran-
scription start site and distal regulatory elements called enhancers. 
Accessibility of the DNA to transcription factors and other transcrip-
tional machinery at these regulatory regions is essential for gene 
expression. Three processes can regulate gene transcription without al-
terations of the DNA sequence, including DNA methylation, modifica-
tions of histone proteins, and the effects of non-coding RNAs. Several 
research papers have now described an essential regulatory role of his-
tone modifications in innate immune memory (van der Heijden et al., 
2018). Also, recently a role for a specific long non-coding RNA molecule 
UMLILO in trained immunity was reported (Fanucchi et al., 2019), while 
the role of DNA methylation has only been suggested in one study in 
BCG-vaccinated subjects (Verma et al., 2017). 
Histone lysine residues can be enzymatically modified by the addi-
tion of methyl groups or acetyl groups which regulate the accessibility of 
the promoter and enhancer regions for the transcriptional machinery. 
Some histone modifications, such as trimethylation of lysine 4 at histone 
3 (H3K4me3), mark active promoters, while H3K4me1 marks distal 
regulatory elements (enhancers). Histone acetyl modifications are 
generally associated with an open active chromatin, e.g. H3K27ac, 
which marks active promoters and enhancers (Saeed et al., 2014). 
Importantly, these histone modifications are written and erased by 
N.P. Riksen and M.G. Netea                                                                                                                                                                                                                 
Molecular Aspects of Medicine 77 (2021) 100897
3
specific epigenetic enzymes (including histone methyltransferases and 
demethylases, histone acetylases and deacetylases), which makes them 
potentially modifiable by drugs targeting these enzymes. 
Stimulation of innate immune cells is accompanied by the rapid 
deposition of these chromatin marks and changes in the DNA methyl-
ation status, which leads to the unfolding of the chromatin and facili-
tates transcription and expression of proinflammatory factors. 
Importantly, in the context of trained immunity, these histone modifi-
cations are only partially removed after cessation of the training stim-
ulus, resulting in a persistent enrichment of promoters of these cytokines 
with H3K4me3 and of enhancers with H3K4me1. This allows quicker 
and enhanced recruitment of transcription factors and gene expression 
after secondary challenge with another stimulus. For detailed informa-
tion about the dynamics and regulation of this epigenetic reprogram-
ming, we refer to previous papers by our group (Saeed et al., 2014; Netea 
et al., 2020; van der Heijden et al., 2018). Thus far, only two specific 
epigenetic enzymes have been characterized that regulate the epigenetic 
remodeling of training. First, the KDM5 family of histone demethylases, 
which are responsible for demethylation of H3K4 appears critical for 
trained immunity: β-glucan training of monocytes resulted in decreased 
biological activity of KDM5 demethylases on day 6 after training, which 
was regulated by changes in intracellular fumarate, which will be dis-
cussed later (Arts et al., 2016). More recently, the lysine methyl-
transferase Set7, which writes H3K4me1 marks, was identified as key 
enzyme necessary for β-glucan-induced trained immunity in vitro and in 
vivo (Keating, Groh, van der Heijden, et al., 2020). 
4. Reprogramming of metabolic pathways in trained immunity 
Just like all other cells, innate immune cells require several meta-
bolic pathways to execute their diverse roles and respond to changing 
micro-environments; the most important pathways include glycolysis, 
the tricarboxylic acid (TCA) cycle and oxidative phosphorylation 
(OXPHOS), the pentose phosphate pathway, fatty acid oxidation, fatty 
acid synthesis and amino acid metabolism. These pathways provide 
energy in the form of ATP, but they also regulate biosynthesis and 
proliferation by providing essential macromolecular building blocks, 
and they regulate redox signaling and intercellular signaling. By doing 
so, they not only follow metabolic demands of the cells and nutrient 
availability, but are able to dictate cellular function themselves, which is 
recently discussed in detail in excellent review papers (O’Neill et al., 
2016). In particular, metabolic pathways can regulate epigenetic pro-
grams by providing intermediate metabolites that can either serve as 
substrates for epigenetic enzymes (e.g. acetylCoA is the major substrate 
for histone acetyltransferases) or as co-activators or co-repressors of 
epigenetic writers or erasers (e.g. the [NAD+]/[NADH] ratio as activator 
of the SIRT1 histone deacetylase, fumarate as inhibitor of the KDM5 
family of histone demethylases, and α-ketoglutarate as cofactor for the 
histone demethylase JMJD3, reviewed in (van der Heijden et al., 2018)). 
Many of these pathways also serve important functions in the 
development of innate immune memory, which we will discuss in detail 
in the next sections. To elucidate which metabolic pathways are 
differentially expressed in trained immunity, Arts et al. recently per-
formed RNA-sequencing and full intracellular metabolome assessment 
at different time points in β-glucan trained primary human isolated 
monocytes (Arts et al., 2016). After 24 h of exposure to β-glucan, the 
RNA expression patterns of metabolic enzymes differed from control 
monocytes, with the largest difference observed after 6 days. Similarly, 
metabolome data showed that at early time points (4 h and 24 h after 
stimulation), only small differences existed between the trained and 
control cells, whereas at day 6, the intracellular metabolome of β-glu-
can-trained cells was clearly different. Altogether, these data indicate 
that major transcriptional changes associated with metabolic pathways 
occur at an early timepoint after β-glucan exposure, which precede the 
metabolic phenotype observed in fully differentiated β-glucan-trained 
macrophages on day 6 (Arts et al., 2016). Integration of the 
Fig. 1. Schematic overview of the intracellular mechanisms operating in monocytes/macrophages to build trained immunity. Depicted are the extracellular 
exogenous and endogenous triggers, the various metabolic pathways that are activated with their most important metabolites, and the bidirectional interaction with 
epigenetic enzymes in the nucleus. 
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transcriptome and metabolome data revealed an upregulation of several 
metabolic pathways in β-glucan-trained macrophages, including 
glycolysis, the pentose phosphate pathway, glutamine metabolism, fatty 
acid synthesis, and cholesterol metabolism. In addition, several inter-
mediary metabolites of the TCA cycle and glutaminolysis were enriched. 
4.1. Glycolysis 
Glycolysis is one of the major metabolic pathways in all cell types to 
provide energy and building blocks for essential biosynthetic pathways. 
It involves the conversion of glucose to pyruvate in the cytosolic 
compartment, which can either by shuttled into the TCA cycle or fer-
mented to lactate. The latter reaction commonly occurs in hypoxic sit-
uations in which OXPHOS is switched off, but can also occur in 
normoxia, which is called aerobic glycolysis. Although glycolysis is 
much less efficient in ATP production than OXPHOS, it is the major 
pathway for energy production in proliferating cells, e.g. tumor cells, 
which was already described by Otto Warburg, (1956). Hence, the 
aerobic glycolysis that is typical of tumor cells has been named the 
Warburg effect. The same glycolytic preference holds true for activated 
immune cells, including LPS-activated M1-macrophages and dendritic 
cells, activated effector T cells, and activated natural killer cells. The 
benefits of switching preferentially to glycolysis are explained by 1) the 
possibility for rapid induction of glycolytic enzymes in situations of 
acute need of rapid energy production, such as inflammation 2) the 
conversion of NAD+ to NADH, which is an important co-factor for many 
enzymes, and 3) the diversion of intermediate products into biosynthetic 
pathways (O’Neill et al., 2016). In the latter regard, 
glucose-6-phosphate fuels the pentose phosphate pathway for the pro-
duction of ribose for nucleotides, 3-phosphoglycerol into the serine 
biosynthetic pathway, and pyruvate into the TCA cycle to provide 
citrate. 
Several lines of evidence point towards a key role for glycolytic 
metabolism in the development of trained immunity in response to the 
exposure to β-glucan and BCG (Arts et al., 2016; Cheng et al., 2014): 
first, there is an upregulation of mRNA expression of glycolytic enzymes 
six days after exposure to the training stimulus (Cheng et al., 2014). 
Second, trained macrophages show increased lactate production, a 
higher glucose consumption, and an increased NAD + to NADH ratio, 
both during the first 24 h of exposure as well as on day 6 in the trained 
macrophage (Arts et al., 2016). Third, glucose flux analyses with nuclear 
magnetic resonance (NMR) with radiolabeled 13C-glucose indeed 
showed increased incorporation of 13C into lactate during the 24 h of 
restimulation with LPS. In addition, incorporation of the 13C-labels was 
also increased in ribosyl-1 which is suggestive of an induction of the 
pentose phosphate pathway (Arts et al., 2016). For both β-glucan and 
BCG, upregulation of glycolysis is secondary to activation of the Akt – 
mTOR – HIF1α pathway. Pharmacological inhibition of this pathway, or 
of glycolysis with 2-deoxyglucose indeed abolishes the augmentation of 
cytokine production capacity (Arts et al., 2016; Cheng et al., 2014). 
Finally, additional proof for a role of glycolysis in trained immunity 
stems from the observations that in cohorts of healthy subjects, single 
nucleotide polymorphisms (SNPs) in key glycolytic enzymes are asso-
ciated with the induction of cytokine production capacity by training of 
the cells ex vivo; this was reported for SNPs in hexokinase 2 (HK2) and 
phosphofructokinase, platelet (PFKP) for training with BCG (Arts et al., 
2016). In vivo, BCG vaccination induced a trained immune phenotype in 
isolated peripheral blood mononuclear cells, which was associated with 
a higher expression of HK2 and PFKP. 
Also for training with oxLDL, an increased glycolytic activity is 
essential for the development of the trained immune phenotype: oxLDL- 
trained macrophages are characterized by an increased extracellular 
acidification rate using Seahorse technology, and pharmacological in-
hibition of glycolysis (either by 2-DG or by inhibition of the inducible 
PFK-2/FBPase isozyme 6-phosphofructo-2-kinase/fructose-2,6-biphos-
phatase 3 (PFKFB3)) prevents trained immunity (Keating et al., 2020). 
In addition, genetic variation in genes encoding PFKFB3 and PFKP were 
associated with the potentiation of TNF-α and IL-6 production upon 
training with oxLDL ex vivo (Keating et al., 2020). 
We recently reported that endogenous adrenal products that are 
associated with hypertension and atherosclerotic cardiovascular dis-
ease, including aldosterone and adrenaline/noradrenaline also induce 
innate immune memory in human isolated primary monocytes (van der 
Heijden et al., 2020; van der Heijden et al., 2020). Remarkable, 
aldosterone-induced trained immunity was not associated with changes 
in ECAR and OCR using Seahorse technology. For the catecholamines, 
however, adaptations in these metabolic pathways strongly associated 
with the effects on cytokine production capacity: the immediate 
immunosuppressive effect of 24 h exposure to adrenaline/noradrenaline 
was associated with reductions in ECAR and OCR, whereas the 
augmented cytokine production capacity that developed six days later 
was associated with increased glycolysis and OXPHOS (van der Heijden 
et al., 2020). 
There is a close bilateral relationship between the upregulation of 
glycolytic metabolism and epigenetic reprogramming. Glycolysis is 
essential for the induction of cytokine production capacity which is 
mediated by enrichment of the promoters of these genes by activating 
histone modifications, including H3K4me3 (Keating et al., 2020) (Arts 
et al., 2016; Cheng et al., 2014). One mechanism that links glycolytic 
activation to epigenetic reprogramming is the dependency of the sirtuin 
family of histone deacytelases (HDACs) on the intracellular NAD +
concentration (Anderson et al., 2017). Indeed, the NAD+/NADP ratio is 
increased in trained macrophages (Cheng et al., 2014) and the induction 
of cytokine production capacity by β-glucan is blunted by 
co-administration of the HDAC inhibitor resveratrol (Cheng et al., 
2014). Conversely, the increased expression of glycolytic enzymes is 
mediated by activating histone modifications itself, and 
co-administration of epigenetic inhibitors, such as the nonspecific 
methyltransferase inhibitor methylthioadenosine or the Set7 methyl-
transferase inhibitor cyproheptadine, prevents the upregulation of 
glycolysis by β-glucan on day 6, whereas it does not affect the lactate 
production in the first 24 h of exposure to β-glucan (Cheng et al., 2014; 
Keating, Groh, van der Heijden, et al., 2020). Interestingly, 
oxLDL-trained macrophages are characterized by an enrichment of 
H3K4me3 on the promoters of PFKFB3 and HK2, which is attenuated by 
pharmacological inhibition of glycolysis, pointing to a self-perpetuating 
epigenetic activation of glycolysis (Keating et al., 2020). 
4.2. Pentose phosphate pathway 
As mentioned before, one of the benefits of glycolytic activation for 
proliferating or inflammatory cells is that it feeds into the pentose 
phosphate pathway, which is important for the production of amino acid 
precursors and nucleotides, necessary for cellular growth and prolifer-
ation. In addition, activation of the PPP generates NADPH, which is 
needed for the production of reactive oxygen species important to 
combat micro-organisms (O’Neill et al., 2016). Both transcriptomic 
analyses as well as flux studies with 13C-labeled glucose point to an 
activation of the oxidative branch of the PPP in macrophages trained 
with BCG or β-glucan (Arts et al., 2016; Arts et al., 2018). However, 
pharmacological blockade of this branch of the PPP did not interfere 
with trained immunity development in vitro showing that the PPP is 
dispensable for trained immunity (Arts et al., 2016; Arts et al., 2016). It 
is logical to assume though that the PPP is essential for persistence of 
trained immunity in vivo by its involvement in the proliferation of 
myeloid progenitor cells, but this has not been investigated. 
4.3. Tricarboxylic acid cycle and oxidative phosphorylation 
In resting or anti-inflammatory immune cells, such as the prototyp-
ical anti-inflammatory IL-4/IL-13 polarized M2-macrophages and Treg 
cells, the TCA cycle (also known as citric acid cycle or Krebs cycle) and 
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subsequent OXPHOS act as the single most important and highly effi-
cient pathway for ATP synthesis (O’Neill et al., 2016). The TCA cycle 
and OXPHOS provide a highly efficient mechanism in which 
glycolysis-derived pyruvate or fatty acids are used for the generation of 
the high-transfer-potential electron carriers nicotinamide dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH2). These redox me-
tabolites subsequently feed electrons into the Electron Transport Chain 
(ETC) to support OXPHOS finally resulting in the generation of ATP by 
ATP synthase (complex V of the ETC). 
Importantly, when needed, the TCA cycle can serve other goals for 
proper cell function other than energy production. When innate immune 
cells, such as monocytes, are stimulated by growth signals or inflam-
matory stimuli, e.g. lipopolysaccharide, the TCA cycle shifts function to 
provide intermediary metabolites for biosynthetic pathways, including 
the production of amino acids and lipids, which is termed cataplerosis. 
The efflux of intermediates for biosynthesis requires replenishment of 
the TCA cycle by nutrients in a process called anaplerosis. In the setting 
of inflammatory stimulation of macrophages (e.g. by LPS), this func-
tional shift involves accumulation of citrate and succinate by the tran-
scriptional repression of isocitrate dehydrogenase (IDH), and inhibition 
of succinate dehydrogenase (SDH) function, respectively (Ryan and 
O’Neill, 2020). In this situation, citrate is transported from the mito-
chondrial matrix into the cytoplasm and converted into acetyl-CoA, 
which can be used for acetylation by acetyltransferases, or fuels syn-
thesis of fatty acids and cholesterol, which are important for the for-
mation of prostaglandins and lipid rafts. Succinate further fuels 
inflammatory activation by various mechanisms including inter-
leuking-1β synthesis by stabilization of hypoxia-inducible factor 
(HIF)-1α (Ryan and O’Neill, 2020). 
Several recent papers have investigated the role of TCA cycle and 
OXPHOS in trained immunity. In general, these studies revealed that the 
TCA cycle remains function for ATP production by OXPHOS, while at 
the same time it provides intermediate metabolites that modulate in-
flammatory function by regulating activity of epigenetic enzymes. 
Analyses of cellular oxygen consumption of in vitro trained human 
primary macrophages, either with a low dose of β-glucan (of 1 μg/ml), 
BCG, oxLDL, or the catecholamines adrenaline and noradrenaline, all 
revealed an augmented basal and maximum oxygen consumption rate 
on day 6 before restimulation of the cells (Arts et al., 2016; van der 
Heijden et al., 2020; Keating, Groh, van der Heijden, et al., 2020; 
Keating et al., 2020). In contrast, a high concentration of β-glucan of 10 
μg/ml, which also potently induce a trained immune response in terms 
of augmentation of cytokine production capacity, induced a classical 
Warburg effect with an increased glycolysis but repression of OXPHOS 
(Cheng et al., 2014). The mechanism of this dose-dependency requires 
further investigation. An additional argument suggesting a role for 
OXPHOS in trained immunity is the finding that in a cohort of healthy 
subjects, genetic variation in NADH:ubiquinone oxidoreductase (com-
plex I of mitochondrial electron transport chain) is associated with 
augmentation of IL-6 production in ex vivo β-glucan trained cells 
(Keating, Groh, van der Heijden, et al., 2020). Similar associations were 
described for genetic variation in IDH and SDH, the genes previously 
described to mediate the repurposing of the TCA cycle in LPS-stimulated 
macrophages (Keating, Groh, van der Heijden, et al., 2020). Finally, 
co-administration of the ATP synthase inhibitor oligomycin during 
LPS-restimulation in β-glucan trained cells prevents the increased 
cytokine production (Keating, Groh, van der Heijden, et al., 2020), 
suggesting that OXPHOS-derived energy production is required for the 
trained immune phenotype. Inhibition of OXPHOS with oligomycin 
during training with BCG, however, did not interfere with the induction 
of cytokine production capacity (Arts et al., 2016). Co-administration of 
metformin with β-glucan or with oxLDL prevents the development of a 
trained macrophage phenotype. Metformin inhibits complex I of the 
respiratory chain which suppresses ATP production (El-Mir et al., 2000). 
However, the effect of metformin on trained immunity can also be 
explained by its inhibition of mTOR through activation of adenosine 
triphosphate dependent protein kinase (AMPK) (Cheng et al., 2014). 
Full metabolic assessment of β-glucan-trained macrophages revealed 
an upregulation of the TCA cycle metabolites succinate, fumarate, and 
malate, and also of 2-hydroxy-glutarate, which is derived from gluta-
minolysis (Arts et al., 2016). The observation that pharmacological in-
hibition of the conversion of glutamine into glutamate prevented trained 
immunity, confirmed that replenishment of the TCA cycle by gluta-
minolysis is essential for trained immunity. Interestingly, exposing 
monocytes to fumarate, but not succinate or malate, for 24 h recapitu-
lated the trained macrophage phenotype in terms of augmented cyto-
kine production capacity. This was accompanied by an enrichment of 
H3K4me3 on the promoters of the cytokine genes, due to a direct 
inhibitory effect of fumarate on the KDM5 family of histone demethy-
lases, which are responsible for demethylation of H3K4 (Arts et al., 
2016). This effect could partly be restored by the addition of 
α-ketoglutarate. 
4.4. Itaconate 
Another metabolite from the TCA cycle that appears to be important 
in modulating trained immunity is itaconate. Itaconate is synthesized 
from the decarboxylation of cis-aconitate in the TCA cycle by the 
enzyme immune-responsive gene 1 (IRG1) (Michelucci et al., 2013). 
Itaconate has long been known to have strong antimicrobial properties, 
and more recently has been described as a natural endogenous break on 
inflammation in innate immune cells, which contributes to the resolu-
tion of inflammation (Hooftman and O’Neill, 2019). Briefly, during LPS 
stimulation in macrophages, itaconate inhibits inflammatory responses, 
notably IL-1β production, by various independent mechanisms, 
including inhibition of SDB, and activation of the master antioxidant 
transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2 
or NRF2) (Mills et al., 2018). In addition, itaconate can increase the 
expression of activating transcription factor 3 (ATF3), which is a nega-
tive regulator of NF-κB zeta (IκBζ), a transcription factor that regulates 
secondary transcriptional responses to TLR activation, including the 
release of IL-6 (Bambouskova et al., 2018). 
In a recent paper, Domínguez-Andrés et al. investigated the role of 
itaconate in innate immune tolerance and training (Dominguez-Andres 
et al., 2019). They underscored the potent anti-inflammatory effects of 
itaconate in macrophages by showing that LPS exposure, which induces 
immune cell tolerance, leads to a rapid increase of itaconate by upre-
gulation of the expression of IRG1. Itaconate subsequently increases 
succinate levels by the inhibition of SDH. Importantly, 
co-administration of β-glucan and LPS prevented this upregulation of 
IRG1 expression, and training with β-glucan was associated with a 
long-lasting inhibition of IRG1 expression as secondary exposure to LPS 
only minimally increased IRG1 expression. These results fit the previous 
observation that β-glucan prevents and reverts LPS-induced tolerance 
(Novakovic et al., 2016). Itaconate itself also modulates trained immu-
nity by its inhibitory effect on SDH: in the context of β-glucan-induced 
trained immunity, the addition of exogenous itaconate (dimethylitaco-
nate) prevents the development of the hyperresponsive trained immune 
phenotype by preventing the accumulation of fumarate. 
In summary, while itaconate inhibits the induction of trained im-
munity, β-glucan-induced trained immunity can revert LPS-induced 
immunoparalysis by inhibiting activation of the IRG1-itaconate-SDH 
axis. 
So, TCA cycle intermediates can impact on cell function by modu-
lating epigenetic enzymes. At the same time, epigenetic processes can 
regulate metabolic functions of monocytes and macrophages. Keating 
et al. recently described a critical role for the methyltransferase Set7 in 
the adaptations of the TCA cycle function and OXPHOS that occur in 
β-glucan trained cells (Keating, Groh, van der Heijden, et al., 2020). 
They validated that in β-glucan trained macrophages, on day 6 the 
intracellular concentrations of the TCA cycle metabolites succinate, 
fumarate, malate, oxaloacetate, and citrate were higher than in 
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non-trained control cells (Keating, Groh, van der Heijden, et al., 2020). 
This increase was prevented for succinate, fumarate, and malate by 
co-incubation of β-glucan with the Set7 inhibitor cyproheptadine (CPH). 
This co-incited with an augmented expression of the enzymes 
Succinate-CoA Ligase GDP/ADP-Forming Subunit Alpha (SUCLG1), the 
B subunit of succinate dehydrogenase (SDHB), fumarate hydratase (FH), 
malate dehydrogenase 2 (MDH2) and citrate synthase (CS) mRNA 
expression, which was prevented by CPH for SDHB, FH, and MDH2. This 
enhanced expression was regulated by Set7 dependent enrichment of 
H3K4me1 at distal enhancers that form regulatory domains with MDH2 
and SDHB (Keating, Groh, van der Heijden, et al., 2020). Setd7 deficient 
mice were used to validate the effect of β-glucan training on TCA cycle 
enzymes in bone marrow progenitor cells and it was shown that mRNA 
expression of MDH2 and SDHB, but not FH1 or Suclg2 was increased by 
β-glucan in wild-type mice, but not in the Setd7 deficient mice (Keating, 
Groh, van der Heijden, et al., 2020). 
4.5. Lipid synthesis pathway 
In the cytosol, citric acid-derived acetyl-CoA can enter the choles-
terol biosynthesis pathway, which is controlled mainly by the enzyme 3- 
hydroxy-3-methylglutaryl CoA reductase. This pathway is important for 
the inflammatory function of immune cells for various reasons. First, 
cholesterol determines the structural integrity and fluidity of the cellular 
membranes and compartmentalization of the membrane in lipid rafts, 
which are important for inflammatory signal transduction pathways. In 
addition, isoprenoid intermediates of the cholesterol synthesis pathway 
can modify the function of multiple proteins by a process called pre-
nylation which can modify the function of these proteins, many of which 
are involved in inflammatory processes. In the context of atheroscle-
rosis, it has been established that cholesterol accumulation in myeloid 
progenitor cells in the bone marrow promotes myelopoiesis and leads to 
an acceleration of atherosclerosis (Yvan-Charvet et al. 2008, 2010; Tall 
and Yvan-Charvet, 2015). Analysis of the transcriptome and metab-
olome of β-glucan trained macrophages revealed, in addition to glycol-
ysis, the PPP, and glutamine metabolism, also an upregulation of 
cholesterol and fatty acid synthesis pathways (Arts et al., 2016; Bek-
kering et al., 2018). Pharmacological inhibition of 3-hydroxy-3-methyl-
glutaryl CoA reductase with statins prevented trained immunity by 
β-glucan and oxLDL in vitro and also in an in vivo model of β-gluca-
n-induced trained immunity in mice. Importantly, pharmacological in-
hibition of 5-fluoromevalonate, which catalyzes the conversion of 
mevalonate-5-PP into isopentyl-PP augmented cytokine production ca-
pacity in the in vitro trained immunity model (Bekkering et al., 2018). 
This finding excludes a role for protein prenylation as well as cholesterol 
synthesis in trained immunity and points to a role for intracellular 
accumulation of mevalonate. Indeed, exposure of human monocytes for 
24 h to mevalonate induced a similar trained immune phenotype with 
enhanced cytokine production, accompanied by an activation of 
glycolysis and an enrichment of H3K4me3 on cytokine gene promoters. 
Additional pharmacological experiments revealed that mevalonate 
induced trained immunity by activation of the insulin-like growth 
factor-1 receptor pathway and subsequent activation of mTOR and 
glycolysis (Bekkering et al., 2018). 
The importance of the mevalonate synthesis pathway for trained 
immunity is further highlighted by the finding that RNA sequencing of 
hematopoietic stem cells from mice seven days after β-glucan adminis-
tration showed an enrichment of the cholesterol biosynthesis pathway 
and especially the mevalonate pathway (Mitroulis et al., 2018). 
In addition to the cholesterol synthesis pathway, citrate-derived 
acetyl-CoA can also fuel fatty acid synthesis, which positively regu-
lates the generation and function of pro-inflammatory immune cells of 
both the innate and adaptive immune systems (O’Neill et al., 2016). 
Several studies have reported that inflammatory stimuli such as LPS 
trigger an increase in fatty acid synthesis in macrophages. The relevance 
of this pathway for the development of atherosclerosis is illustrated by 
the observation that in atherosclerosis-prone ApoE − /− mice, 
macrophage-targeted deletion of Fasn (the gene that encodes fatty acid 
synthase) reduces atherosclerotic plaque formation and foam cell for-
mation (Schneider et al., 2010). β-Glucan trained macrophages show an 
upregulation of the fatty acid synthase pathway, but pharmacological 
inhibition of this pathway during the 24 h exposure to β-glucan did not 
interfere with trained immunity (Arts et al., 2016). Fatty acid synthesis 
also appears to be essential for trained immunity induced by aldosterone 
(van der Heijden et al., 2020). As mentioned before, brief exposure of 
human monocytes to aldosterone also enhances cytokine production 
capacity after restimulation with LPS and the TLR2 ligand Pam3Cys, and 
this was not associated with activation of glycolysis or oxidative phos-
phorylation. Four hours after restimulation with Pam3Cys however, the 
aldosterone-trained cells showed an upregulation of various genes that 
are central to the fatty acid synthesis pathway, fatty acid elongation, and 
the formation of very long chain fatty acids, compared to 
vehicle-exposed cells. Furthermore, these genes showed enrichment of 
H3K4me3 on their respective promoters. Preincubation of the 
aldosterone-trained cells with the fatty acid synthesis inhibitor cerulenin 
before the restimulation with Pam3Cys completely abolished the 
augmentation of cytokine production capacity (van der Heijden et al., 
2020). 
The fatty acid oxidation (FAO) pathways occurs in the mitochondrial 
matrix and allows for the conversion of fatty acids, after transport from 
the cytosol via carnitine palmitoyl transferase 1, into acetyl-CoA, NADH, 
and FADH2, which are further used in the TCA cycle for energy pro-
duction. FAO also importantly regulate immune cell function, being the 
primary source of energy production used by anti-inflammatory IL-4/IL- 
13 activated (‘M2’) macrophages (Van den Bossche, O’Neill, and Menon, 
2017; Huang et al., 2014). LPS/IFNγ activated (‘M1’) macrophages on 
the other hand down-regulate FAO, favoring glycolytic metabolism for 
their energy demands. FAO has not yet been studied in the context of 
trained immunity. 
5. Clinical implications and future directions 
The studies summarized above have provided a detailed mechanistic 
framework on how monocytes and macrophages can build an immu-
nological memory and how trained monocytes can persist for months in 
vivo despite their short circulating half-life. Within the cells, activation 
of various metabolic pathways and repurposing of intermediate me-
tabolites strongly interact with epigenetic enzymes to mold a chromatin 
landscape that facilitates persistent hyperresponsiveness to a subsequent 
stimulation. Similar processes occur in myeloid progenitors in the bone 
marrow ensuring persistence of circulating trained monocytes for 
months after a transient trigger for training, such as an infection. 
Since accumulating evidence points to an important role for trained 
immunity in the host defense against infectious threats as well as in the 
pathophysiology of non-infectious chronic inflammatory diseases, the 
intracellular machinery that regulates training offers exciting novel 
pharmacological targets. The potential clinical relevance of trained 
immunity has been expanded further by recent observations that 1) 
other cell types are also able to build trained immunity-like memory 
(Hamada et al., 2018; Netea et al., 2020) and 2) trained immunity might 
also contribute to additional clinical conditions (Netea et al., 2020). 
With regard to the first series of observations, trained immunity has also 
been shown to occur in natural killer cells (NK cells) (Kleinnijenhuis 
et al., 2014; Gamliel et al., 2018), and dendritic cells (Hole et al., 2019). 
Interestingly, memory responses resembling innate immune memory, 
and making use of overlapping epigenetic and metabolic mechanisms, 
can also occur in non-immune cells, including stromal cells and 
epithelial cells. As such, endothelial cells and vascular smooth muscle 
cells also show hyperinflammatory responses following brief exposure to 
glucose or oxLDL (El-Osta et al., 2008; Schnack et al., 2019). Epithelial 
stem cells also maintain chromosomal accessibility at key stress 
response genes that are activated by a primary danger stimulus (Naik 
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et al., 2017). Similarly, cerebral microglia cells can build a long-term 
pro-inflammatory phenotype by epigenetic programs that can last for 
at least six months after peripherally applied inflammatory stimuli 
(Wendeln et al., 2018). This identification of multiple cell types in the 
literature that are able to build inflammatory memory has gone hand in 
hand with an expansion of the clinical scenarios in which trained im-
munity might be involved, including atherosclerosis (Riksen, 2019), 
neurogenerative diseases including cerebral small vessel disease (Wen-
deln et al., 2018; Noz et al., 2018), and organ transplant rejection (Braza 
et al., 2018). 
As such, the metabolic and epigenetic machinery that regulates the 
immunological memory in the various cell types offers an exciting and 
extensive array of novel targets for pharmacological strategies, which 
have recently been described by Mulder et al., (2019). Boosting trained 
immunity, e.g. by BCG vaccination, can improve protection against in-
fections in susceptible populations. In addition, boosting trained im-
munity might reverse immune paralysis in patients with severe 
infections; indeed, in isolated human monocytes, β-glucan can reverse 
the LPS-induced tolerance and ex vivo β-glucan treatment of monocytes 
from volunteers with experimental endotoxemia re-instates their ca-
pacity for cytokine production (Novakovic et al., 2016). Finally, pro-
moting trained immunity could be developed as an additional strategy in 
malignant diseases (Fig. 2). In contrast, drugs that interfere with trained 
immunity could be beneficial in patients with chronic inflammatory 
diseases, including atherosclerosis, auto-immune disorders, and organ 
rejection after transplantation. 
Several existing drugs target one of the metabolic pathways that 
drive trained immunity. Statins inhibit 3-hydroxy-3-methylglutaryl CoA 
reductase and prevent trained immunity induction by β-glucan and 
oxLDL in vitro (Bekkering et al., 2018). In contrast, statins are not able to 
revert the trained immune phenotype in monocytes once this has been 
established: monocytes isolated from patients with an increased car-
diovascular risk due to hypercholesterolemia have an augmented cyto-
kine production capacity that is driven by epigenetic reprogramming 
and this trained phenotype persisted despite cholesterol lowering with 
statins during three months (Bekkering et al., 2019). The anti-
hyperglycemic drug metformin inhibits the mTOR pathway by acti-
vating adenosine monophosphate activated protein kinase (AMPK). 
Given the key role for mTOR in the glycolytic activation necessary for 
training, it is not surprising that metformin can prevent trained immu-
nity, both by β-glucan as well as by oxLDL (Keating et al., 2020). This 
mechanism could theoretically contribute to the anti-atherosclerotic 
effects of metformin in clinical trials. 
Interfering with the metabolic processes that are involved in the 
regulation of trained immunity is challenging, mainly because these 
processes are general processes that are used by all cell types for survival 
and function. Specificity for trained immune processes can be increased 
by pharmacokinetic strategies that improve the delivery of the 
pharmaceutical compound to the specific cell type in which trained 
immunity contributes to disease pathophysiology, e.g. the macrophages 
in atherosclerotic plaques. This is possible with the use of nano-
biologicals, e.g. recombinant high-density lipoprotein (HDL) particles 
which specifically target macrophages (Mulder et al., 2019). Previous 
studies have shown that these HDL particles loaded with drugs that 
interfere with trained immunity, including statins can suppress athero-
sclerotic plaque inflammation (Tang et al., 2015) (Duivenvoorden et al., 
2014). Also, in a mouse model of transplantation, a short-term 
mTOR-specific HDL-nanobiological treatment averted macrophage 
aerobic glycolysis and the epigenetic modifications underlying inflam-
matory cytokine production and improved graft survival (Braza et al., 
2018). Yet another way to prevent side effects and toxicity is to only 
partly inhibit metabolic pathways that are upregulated in trained im-
munity. In isolated human monocytes inhibition of the inducible 
glycolytic enzyme PFKFB3 (6-phosphofructo-2-kinase/fructose-2, 
6-bisphosphatase 3) with the small-molecule 3PO (3-[3-pyr-
idinyl]-1-[4-pyridinyl]-2-propen-1-one) prevents oxLDL-induced 
trained immunity in vitro (Keating et al., 2020). Interestingly, 3-PO 
only partially inhibits glycolysis and systemic treatment of atheroscle-
rosis prone mice with 3-PO significantly reduces atherosclerotic lesion 
development (Perrotta et al., 2020). This is due to the fact that inhibiting 
endothelial cell glycolysis limits intraplaque neovascularization, but it 
cannot be excluded that this treatment strategy also prevented trained 
immunity in innate immune cells. A final strategy that can potentially 
limit side effects of interfering with trained immunity metabolic path-
ways is to exploit the memory aspect trained immunity. A pharmaco-
logical intervention that prevents trained immunity needs to be given 
during only the short period that the trained immunity is switched on, e. 
g. during acute infections, immediately after myocardial infarction, or 
after organ transplantation), which does not interfere with future plas-
ticity of the innate immune system. 
In conclusion, we foresee that the rapidly expanding knowledge 
about the intracellular metabolic and epigenetic processes that modu-
late trained immunity will stimulate the development of novel phar-
macological compounds for patients in various clinical settings. 
Targeted delivery of these compounds to the specific trained cells in a 
time- and site-specific manner is needed to limit side unwanted side 
effects and increase the therapeutic index. 
Funding 
N.P.R. and M.G.N. received funding from the European Union Ho-
rizon 2020 research and innovation program REPROGRAM under grant 
agreement No 667837, an IN-CONTROL CVON grant from the Dutch 
Heart Foundation (CVON 2012-03 and CVON 2018-27). M.G.N is 
further supported by an ERC Advanced Grant (833247) and a 
Netherlands Organization for Scientific Research Spinoza Grant [NWO 
Fig. 2. Schematic representation of the 
various cell types that are able to build 
trained immunity or comparable inflamma-
tory memory characteristics, including 
monocytes, macrophages, myeloid progeni-
tor cells, NK cells, dendritic cells, microglia, 
endothelial cells, and vascular smooth mus-
cle cells. Trained immunity can either 
improve host defense against infections or 
cancer, or be maladaptive in situations of 
chronic inflammation. Therefore, suppres-
sion of trained immunity might be beneficial 
in situations of chronic inflammatory dis-
eases, such as atherosclerosis, or transplant 
rejection. On the other hand, boosting 
trained immunity might improve host de-
fense against infections and might be bene-
ficial in patients with cancer.   
N.P. Riksen and M.G. Netea                                                                                                                                                                                                                 
Molecular Aspects of Medicine 77 (2021) 100897
8
SPI 94–212]. NPR is recipient of a grant of the ERA-CVD Joint Trans-
national Call 2018, which is supported by the Dutch Heart Foundation 
(JTC 2018, project MEMORY); 2018T093). 
References 
Anderson, K.A., Madsen, A.S., Olsen, C.A., Hirschey, M.D., 2017. Metabolic control by 
sirtuins and other enzymes that sense NAD(+), NADH, or their ratio. Biochim. 
Biophys. Acta Bioenerg. 1858 (12), 991–998. 
Arts, R.J., Carvalho, A., La Rocca, C., Palma, C., Rodrigues, F., Silvestre, R., 
Kleinnijenhuis, J., Lachmandas, E., Goncalves, L.G., Belinha, A., Cunha, C., 
Oosting, M., Joosten, L.A., Matarese, G., van Crevel, R., Netea, M.G., 2016. 
Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 17 (10), 
2562–2571. 
Arts, R.J., Novakovic, B., Ter Horst, R., Carvalho, A., Bekkering, S., Lachmandas, E., 
Rodrigues, F., Silvestre, R., Cheng, S.C., Wang, S.Y., Habibi, E., Goncalves, L.G., 
Mesquita, I., Cunha, C., van Laarhoven, A., van de Veerdonk, F.L., Williams, D.L., 
van der Meer, J.W., Logie, C., O’Neill, L.A., Dinarello, C.A., Riksen, N.P., van 
Crevel, R., Clish, C., Notebaart, R.A., Joosten, L.A., Stunnenberg, H.G., Xavier, R.J., 
Netea, M.G., 2016. Glutaminolysis and fumarate accumulation integrate 
immunometabolic and epigenetic programs in trained immunity. Cell Metabol. 24 
(6), 807–819. 
Arts, R.J.W., Moorlag, Sjcfm, Novakovic, B., Li, Y., Wang, S.Y., Oosting, M., Kumar, V., 
Xavier, R.J., Wijmenga, C., Joosten, L.A.B., Reusken, Cbem, Benn, C.S., Aaby, P., 
Koopmans, M.P., Stunnenberg, H.G., van Crevel, R., Netea, M.G., 2018. BCG 
vaccination protects against experimental viral infection in humans through the 
induction of cytokines associated with trained immunity. Cell Host Microbe 23 (1), 
89–100 e5.  
Bambouskova, M., Gorvel, L., Lampropoulou, V., Sergushichev, A., Loginicheva, E., 
Johnson, K., Korenfeld, D., Mathyer, M.E., Kim, H., Huang, L.H., Duncan, D., 
Bregman, H., Keskin, A., Santeford, A., Apte, R.S., Sehgal, R., Johnson, B., 
Amarasinghe, G.K., Soares, M.P., Satoh, T., Akira, S., Hai, T., de Guzman Strong, C., 
Auclair, K., Roddy, T.P., Biller, S.A., Jovanovic, M., Klechevsky, E., Stewart, K.M., 
Randolph, G.J., Artyomov, M.N., 2018. Electrophilic properties of itaconate and 
derivatives regulate the IkappaBzeta-ATF3 inflammatory axis. Nature 556 (7702), 
501–504. 
Bekkering, S., Arts, R.J.W., Novakovic, B., Kourtzelis, I., van der Heijden, Cdcc, Li, Y., 
Popa, C.D., Ter Horst, R., van Tuijl, J., Netea-Maier, R.T., van de Veerdonk, F.L., 
Chavakis, T., Joosten, L.A.B., van der Meer, J.W.M., Stunnenberg, H., Riksen, N.P., 
Netea, M.G., 2018. Metabolic induction of trained immunity through the mevalonate 
pathway. Cell 172 (1–2), 135–146 e9. 
Bekkering, S., Blok, B.A., Joosten, L.A., Riksen, N.P., van Crevel, R., Netea, M.G., 2016. 
In vitro experimental model of trained innate immunity in human primary 
monocytes. Clin. Vaccine Immunol. 23 (12), 926–933. 
Bekkering, S., Joosten, L.A., van der Meer, J.W., Netea, M.G., Riksen, N.P., 2013. Trained 
innate immunity and atherosclerosis. Curr. Opin. Lipidol. 24 (6), 487–492. 
Bekkering, S., Quintin, J., Joosten, L.A., van der Meer, J.W., Netea, M.G., Riksen, N.P., 
2014. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine 
production and foam cell formation via epigenetic reprogramming of monocytes. 
Arterioscler. Thromb. Vasc. Biol. 34, 1731–1738. 
Bekkering, S., Stiekema, L.C.A., Bernelot Moens, S., Verweij, S.L., Novakovic, B., 
Prange, K., Versloot, M., Roeters van Lennep, J.E., Stunnenberg, H., de Winther, M., 
Stroes, E.S.G., Joosten, L.A.B., Netea, M.G., Riksen, N.P., 2019. Treatment with 
statins does not revert trained immunity in patients with familial 
hypercholesterolemia. Cell Metabol. 30 (1), 1–2, 2019 Jul 2.  
Bekkering, S., van den Munckhof, I., Nielen, T., Lamfers, E., Dinarello, C., Rutten, J., de 
Graaf, J., Joosten, L.A., Netea, M.G., Gomes, M.E., Riksen, N.P., 2016. Innate 
immune cell activation and epigenetic remodeling in symptomatic and 
asymptomatic atherosclerosis in humans in vivo. Atherosclerosis 254, 228–236. 
Benn, C.S., Netea, M.G., Selin, L.K., Aaby, P., 2013. A small jab - a big effect: nonspecific 
immunomodulation by vaccines. Trends Immunol. 34 (9), 431–439. 
Braza, M.S., van Leent, M.M.T., Lameijer, M., Sanchez-Gaytan, B.L., Arts, R.J.W., Perez- 
Medina, C., Conde, P., Garcia, M.R., Gonzalez-Perez, M., Brahmachary, M., Fay, F., 
Kluza, E., Kossatz, S., Dress, R.J., Salem, F., Rialdi, A., Reiner, T., Boros, P., 
Strijkers, G.J., Calcagno, C.C., Ginhoux, F., Marazzi, I., Lutgens, E., Nicolaes, G.A.F., 
Weber, C., Swirski, F.K., Nahrendorf, M., Fisher, E.A., Duivenvoorden, R., Fayad, Z. 
A., Netea, M.G., Mulder, W.J.M., Ochando, J., 2018. Inhibiting inflammation with 
myeloid cell-specific nanobiologics promotes organ transplant acceptance. Immunity 
49 (5), 819–828 e6. 
Cheng, S.C., Quintin, J., Cramer, R.A., Shepardson, K.M., Saeed, S., Kumar, V., 
Giamarellos-Bourboulis, E.J., Martens, J.H., Rao, N.A., Aghajanirefah, A., 
Manjeri, G.R., Li, Y., Ifrim, D.C., Arts, R.J., van der Meer, B.M., Deen, P.M., Logie, C., 
O’Neill, L.A., Willems, P., van de Veerdonk, F.L., van der Meer, J.W., Ng, A., 
Joosten, L.A., Wijmenga, C., Stunnenberg, H.G., Xavier, R.J., Netea, M.G., 2014. 
mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained 
immunity. Science 345 (6204), 1250684. 
Christ, A., Gunther, P., Lauterbach, M.A.R., Duewell, P., Biswas, D., Pelka, K., Scholz, C. 
J., Oosting, M., Haendler, K., Bassler, K., Klee, K., Schulte-Schrepping, J., Ulas, T., 
Moorlag, Sjcfm, Kumar, V., Park, M.H., Joosten, L.A.B., Groh, L.A., Riksen, N.P., 
Espevik, T., Schlitzer, A., Li, Y., Fitzgerald, M.L., Netea, M.G., Schultze, J.L., Latz, E., 
2018. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 
172 (1–2), 162–175 e14.  
Cirovic, B., de Bree, L.C.J., Groh, L., Blok, B.A., Chan, J., van der Velden, W.J.F.M., 
Bremmers, M.E.J., van Crevel, R., Handler, K., Picelli, S., Schulte-Schrepping, J., 
Klee, K., Oosting, M., Li, Y., Benn, C.S., Schultze, J.L., Joosten, L.A.B., Curtis, N., 
Netea, M.G., Schlitzer, A., 2020. Human Bacille Calmette-Guérin vaccination elicits 
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